A Single Dose PD & PK Study With Two Formulations of Abediterol in Patients With Asthma
Status:
Completed
Trial end date:
2016-11-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the pharmacodynamics of single doses of
abediterol given by 2 different devices in participants with asthma. Abediterol (AZD0548) is
a potential for once daily treatment of asthma and chronic obstructive pulmonary disease
(COPD) in fixed dose combination (FDC) with an inhaled corticosteroid (ICS) or a novel
anti-inflammatory agent. The aim of the clinical studies is to enable further investigations
in participants with asthma and COPD to evaluate and develop abediterol as an effective long
acting bronchodilator with an acceptable safety profile compared to other inhaled
bronchodilators on the market, for the treatment of asthma and COPD.